Intellia Therapeutics Inc (NTLA) Stake Lifted by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC lifted its position in shares of Intellia Therapeutics Inc (NASDAQ:NTLA) by 113.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 17,100 shares of the company’s stock after purchasing an additional 9,100 shares during the period. Nisa Investment Advisors LLC’s holdings in Intellia Therapeutics were worth $489,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the company. Wells Fargo & Company MN grew its stake in Intellia Therapeutics by 127.1% in the 1st quarter. Wells Fargo & Company MN now owns 78,958 shares of the company’s stock valued at $1,664,000 after buying an additional 44,191 shares during the last quarter. Schwab Charles Investment Management Inc. grew its stake in Intellia Therapeutics by 15.5% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 91,385 shares of the company’s stock valued at $1,928,000 after buying an additional 12,256 shares during the last quarter. BlackRock Inc. grew its stake in Intellia Therapeutics by 0.7% in the 1st quarter. BlackRock Inc. now owns 1,722,962 shares of the company’s stock valued at $36,338,000 after buying an additional 12,015 shares during the last quarter. JPMorgan Chase & Co. grew its stake in Intellia Therapeutics by 675.6% in the 1st quarter. JPMorgan Chase & Co. now owns 27,884 shares of the company’s stock valued at $588,000 after buying an additional 24,289 shares during the last quarter. Finally, Commonwealth Equity Services LLC acquired a new position in Intellia Therapeutics in the 1st quarter valued at about $204,000. Institutional investors own 66.47% of the company’s stock.

Shares of Intellia Therapeutics stock opened at $16.98 on Thursday. Intellia Therapeutics Inc has a 1-year low of $16.33 and a 1-year high of $35.99. The company has a market cap of $860.89 million, a PE ratio of -9.03 and a beta of 3.13.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings results on Wednesday, October 31st. The company reported ($0.53) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.49) by ($0.04). Intellia Therapeutics had a negative return on equity of 31.54% and a negative net margin of 284.56%. The firm had revenue of $7.41 million for the quarter, compared to the consensus estimate of $11.58 million. During the same period last year, the company posted ($0.44) EPS. The business’s revenue was up 1.2% on a year-over-year basis. On average, research analysts forecast that Intellia Therapeutics Inc will post -1.97 earnings per share for the current year.

A number of research analysts have issued reports on NTLA shares. Raymond James started coverage on shares of Intellia Therapeutics in a research report on Thursday, September 20th. They set a “market perform” rating on the stock. BidaskClub lowered shares of Intellia Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, September 22nd. ValuEngine lowered shares of Intellia Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, September 22nd. Credit Suisse Group started coverage on shares of Intellia Therapeutics in a research report on Monday. They set a “neutral” rating and a $24.00 target price on the stock. Finally, Chardan Capital restated a “buy” rating and set a $57.50 target price on shares of Intellia Therapeutics in a research report on Friday, August 24th. One analyst has rated the stock with a sell rating, six have given a hold rating and five have assigned a buy rating to the company’s stock. Intellia Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $38.70.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs.

Featured Story: How does inflation affect different investments?

Want to see what other hedge funds are holding NTLA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intellia Therapeutics Inc (NASDAQ:NTLA).

Institutional Ownership by Quarter for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply